Thermo Fisher Scientific Inc Stock (TMO) Moved Up by 5.14% on May 28: Drivers Behind the Movement

Thermo Fisher Scientific Inc (TMO) moved up by 5.14%. The Healthcare Services & Equipment sector is up by 1.19%. The company outperformed the industry. Top 3 stocks by turnover in the sector: Boston Scientific Corp (BSX) down 2.48%; Thermo Fisher Scientific Inc (TMO) up 5.14%; Unitedhealth Group Inc (UNH) up 0.52%.

What is driving Thermo Fisher Scientific Inc (TMO)’s stock price up today?

Thermo Fisher Scientific (TMO) experienced an upward movement in its stock on May 28, 2026, driven by several positive developments across financial performance, product innovation, and strategic positioning.

The company recently reported strong first-quarter 2026 results, surpassing analyst expectations for both earnings per share (EPS) and revenue. Adjusted EPS grew by 6% and revenue increased by 6% compared to the prior year. This financial outperformance was coupled with an upward revision of the full-year 2026 adjusted EPS guidance, indicating a confident outlook from management. The company also declared a quarterly dividend, signaling commitment to shareholder returns.

A significant catalyst for the positive sentiment appears to be the unveiling of new advanced mass spectrometers, the Thermo Scientific Orbitrap Tribrid Apex and the Thermo Scientific Orbitrap Excedion, at a key industry conference. These innovations are designed to address the growing demand for high-quality data in research and pharmaceutical development, particularly in advanced proteomics, multiomics, biologics, and genetic therapies. The integration of high-performance technology with AI-driven software in these instruments is expected to enhance efficiency in data production and accelerate the development of targeted therapies. This product launch aligns with broader industry trends toward automation, AI integration, and advanced analytical technologies in life sciences.

Furthermore, institutional investor activity has been noted, with several firms, including Baker Avenue Asset Management LP and Geode Capital Management LLC, increasing their holdings in TMO during the fourth quarter. This suggests a growing institutional confidence in the company's prospects. Analyst sentiment remains largely positive, with a consensus rating of "Moderate Buy" and an average price target that implies potential upside. While some analysts recently adjusted price targets, the overall outlook remains favorable, with expectations for continued revenue growth across various segments and robust EPS growth for the coming year.

Additionally, Thermo Fisher Scientific announced the launch of a new bioanalytical and biomarker laboratory in Sweden, expanding its global network to support pharmaceutical and biotechnology companies in drug development. This strategic expansion reinforces the company's investment in the European life sciences sector and its efforts to meet increasing demand for sophisticated drug development solutions. The company also hosted an Investor Day, highlighting its industry leadership, growth outlook, and long-term value creation strategies, including disciplined mergers and acquisitions and capital return to shareholders. However, it is worth noting that the company previously announced an agreement to sell its microbiology business, which is expected to be dilutive to adjusted EPS in the first full year after closing.

Technical Analysis of Thermo Fisher Scientific Inc (TMO)

Technically, Thermo Fisher Scientific Inc (TMO) shows a MACD (12,26,9) value of [-11.48], indicating a neutral signal. The RSI at 45.27 suggests neutral condition and the Williams %R at -53.49 suggests oversold condition. Please monitor closely.

Fundamental Analysis of Thermo Fisher Scientific Inc (TMO)

Thermo Fisher Scientific Inc (TMO) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $44.56B, ranking 2 in the industry. The net profit is $6.70B, ranking 1 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $618.09, a high of $750.00, and a low of $490.00.

More details about Thermo Fisher Scientific Inc (TMO)

Company Specific Risks:

• Shareholders did not approve a non-binding advisory proposal on executive compensation at the recent Annual Meeting, signaling corporate governance concerns and investor discontent.
• The company's reported 1% organic revenue growth in Q1 2026 missed analyst forecasts, leading to a mixed investor response and skepticism regarding its ambitious long-term organic growth targets.
• Recent analyst downgrades and price target cuts cite concerns over the dilutive impact of ongoing business divestitures and a challenging fundamental backdrop.
• Thermo Fisher Scientific continues to face significant macroeconomic headwinds, including a sustained pullback in global biopharmaceutical spending and softness in the China market, which are expected to persist throughout 2026.